Payment overview · 2025
General Payments
$490.78
26 reported records · 11 companies
Healthcare provider profile · identity verified
Samuel Moskowitz, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EDENTON, NC · NPI 1932336161
Verified facts
What the public records show
CMS Open Payments records show Samuel Moskowitz, M.D. received $490.78 in general payments during 2025 across 26 reported records.
PFIZER INC. accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.35 | 18.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.86 | 17.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.81 | 13.0% | 3 | 2025 |
| Endo USA, Inc. | Unresolved — no canonical attribution shown | $49.70 | 10.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $49.08 | 10.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.10 | 9.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.62 | 6.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.66 | 4.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.28 | 4.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.07 | 4.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.25 | 1.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $490.78 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $87.86 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.06 | 3 | 2025 |
Source payment records
|
|||||
| AVEED Normalized: aveed |
Biological | Endo USA, Inc. | $49.70 | 2 | 2025 |
Source payment records
|
|||||
| XIAFLEX Normalized: xiaflex |
Biological | Endo USA, Inc. | $49.70 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $49.08 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.10 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.10 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.62 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.25 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 104 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 577 | 150 |
| Atorvastatin Calcium | Atorvastatin Calcium | 519 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 464 | 125 |
| Lisinopril | Lisinopril | 390 | 102 |
| Pravastatin Sodium | Pravastatin Sodium | 328 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 311 | 75 |
| Gabapentin | Gabapentin | 299 | 90 |
| Omeprazole | Omeprazole | 283 | 79 |
| Potassium Chloride | Potassium Chloride | 277 | 60 |
| Celecoxib | Celecoxib | 254 | 60 |
| Losartan Potassium | Losartan Potassium | 253 | 59 |
| Metformin Hcl | Metformin Hcl | 238 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 55 |
| Montelukast Sodium | Montelukast Sodium | 212 | 57 |
| Furosemide | Furosemide | 198 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 41 |
| Simvastatin | Simvastatin | 143 | 34 |
| Glimepiride | Glimepiride | 142 | 38 |
| Chlorthalidone | Chlorthalidone | 133 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 37 |
| Carvedilol | Carvedilol | 122 | 29 |
| Prednisone | Prednisone | 122 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 62 |
| Januvia | Sitagliptin Phosphate | 117 | 28 |
| Metformin Hcl Er | Metformin Hcl | 112 | 33 |
| Trazodone Hcl | Trazodone Hcl | 111 | 26 |
| Eliquis | Apixaban | 104 | 17 |
| Spironolactone | Spironolactone | 104 | 27 |
| Tramadol Hcl | Tramadol Hcl | 104 | 25 |
| Jardiance | Empagliflozin | 100 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 98 | 18 |
| Mirtazapine | Mirtazapine | 93 | 30 |
| Sertraline Hcl | Sertraline Hcl | 92 | 19 |
| Ozempic | Semaglutide | 89 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 16 |
| Allopurinol | Allopurinol | 83 | 19 |
| Buspirone Hcl | Buspirone Hcl | 82 | 18 |
| Colchicine | Colchicine | 74 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 17 |
| Meclizine Hcl | Meclizine Hcl | 68 | 23 |
| Xarelto | Rivaroxaban | 68 | 15 |
| Famotidine | Famotidine | 67 | 16 |
| Fenofibrate | Fenofibrate | 67 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 19 |
| Klor-Con M20 | Potassium Chloride | 66 | 23 |
| Alprazolam | Alprazolam | 64 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 18 |
| Finasteride | Finasteride | 58 | 13 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Atenolol | Atenolol | 54 | 13 |
| Meloxicam | Meloxicam | 54 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 47 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 46 | 19 |
| Azithromycin | Azithromycin | 45 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 14 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Rybelsus | Semaglutide | 34 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 27 | 22 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Nystatin | Nystatin | 25 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Klor-Con M10 | Potassium Chloride | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 18 |
| Valsartan | Valsartan | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lite Touch | Pen Needle, Diabetic | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Mitigare | Colchicine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $490.78 · 26 records | PFIZER INC. | ABRYSVO, AVEED, CAPVAXIVE, COMIRNATY, ELIQUIS, GARDASIL 9, JARDIANCE, Korlym, Leqembi, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, VOQUEZNA, VRAYLAR, Wegovy, XIAFLEX, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error